Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.39

0.0%

Nov 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (369)	8/25/1999 1:30:00 AM
From: scaram(o)uche	Read Replies (3) of 1475

Dave: Correct, no partner yet for AlloMune. >> Or package the needed tools and drugs [even though not proprietary to BTRN] and do training? << Correct.... the centrifugation unit from Dendreon together with other stuff and 507. Remember that 507 is proprietary, both the antibody itself and any antibody that recognizes the same CD2 epitope. However, I haven't seen the manuscript yet, and, for all I know, 507 wasn't used in the process. I presume that it was, and I've emailed asking for a FAX of the article. >> Haven't been around bio enough to have seen an operation patented << Keep watching......... Title: MIXED CHIMERISM AND TOLERANCE Publication date: 1999-06-02 Inventor(s): SYKES MEGAN (US) Applicant(s): GEN HOSPITAL CORP (US) Requested Patent: EP0918524 A 19990602 Application Number: EP19970926433 19970508 Priority Number(s): WO1997US07874 19970508; US19960017099P 19970508 IPC Classification: A61K31/555 ; A61K35/23 ; A61K35/28 ; A61K35/407 ; A61K38/00 ; A61K39/00 ; A61K39/395 Published doc.: WO9741863

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next